13251-86-0

Basic information

• Product Name: (6alpha,17beta)-17-hydroxy-6-methylandrost-4-en-3-one
• Synonyms: 17beta-Hydroxy-6alpha-methylandrost-4-en-3-one; 6alpha-Methyltestosterone; androst-4-en-3-one, 17-hydroxy-6-methyl-, (6alpha,17beta)-
• CAS NO: 13251-86-0
• Molecular Formula: C₂₀H₃₀O₂
• Molecular Weight: 302.451
• Mol File: 13251-86-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 438.9°C at 760 mmHg
• Flash Point: 187.1°C
• Density: 1.1g/cm³
• Vapor Pressure: 1.52E-09mmHg at 25°C
• Refractive Index: 1.553
• CAS DataBase Reference: (6alpha,17beta)-17-hydroxy-6-methylandrost-4-en-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: (6alpha,17beta)-17-hydroxy-6-methylandrost-4-en-3-one(13251-86-0)
• EPA Substance Registry System: (6alpha,17beta)-17-hydroxy-6-methylandrost-4-en-3-one(13251-86-0)

Safety Data

• Hazardous Substances Data: 13251-86-0(Hazardous Substances Data)

Usage

Description

(6alpha,17beta)-17-hydroxy-6-methylandrost-4-en-3-one is a synthetic steroid derived from testosterone, belonging to the class of androgens and anabolic steroids. It is recognized for its ability to stimulate muscle growth, enhance strength, and boost athletic performance. Despite its benefits, it also poses health risks such as liver damage, cardiovascular issues, and hormonal imbalances. Consequently, its use is regulated by athletic organizations and government agencies to prevent abuse and mitigate potential health hazards.

Uses

Used in Bodybuilding and Athletic Performance Enhancement:
(6alpha,17beta)-17-hydroxy-6-methylandrost-4-en-3-one is utilized as a performance-enhancing substance for athletes and bodybuilders. It is employed to increase muscle mass, improve physical strength, and elevate overall athletic performance. However, its use is controversial due to the potential for side effects and is subject to regulation to ensure fair competition and safeguard the health of athletes.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (6alpha,17beta)-17-hydroxy-6-methylandrost-4-en-3-one may be used as an active ingredient in the development of medications aimed at treating conditions related to muscle wasting or other muscle-related disorders. Its anabolic properties make it a potential candidate for therapeutic applications, provided that the risks and benefits are carefully evaluated and managed.

Upstream product

• 2241-94-3 6α-methylandrost-4-ene-3,17-dione 
• 110248-80-1 5,17β-dihydroxy-6β-methyl-5α-androstan-3-one 
• 13252-06-7 17β-hydroxy-6β-methyl-4-androsten-3-one 
• 50909-19-8 3,3-ethanediyldioxy-5,6α-epoxy-5α-androstan-17β-ol 
• 975-57-5 3,3-(ethylenedioxy)-5-androsten-17β-ol 
• 896440-84-9 6β-methyl-androst-4-ene-3β,17β-diol 
• 113549-50-1 3,3-ethanediyldioxy-6β-methyl-5α-androstane-5,17β-diol 
• 114507-79-8 3β,17β-diacetoxy-6β-methyl-androst-4-ene 
• 115728-88-6 3β.17β-diacetoxy-6β-methyl-5α-androstanol-(5) 

Downstream Products

• 2241-94-3 6α-methylandrost-4-ene-3,17-dione 

Relevant articles and documents

ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT

The present invention relates to methods of providing male contraception using a specified androgen without the need of a separate sterilizing agent. The invention also describes methods for non-contraceptive androgen replacement and devices useful for carrying out both processes.

Method for androgen supplementation

A particular group of androgens is not metabolized to their 5α-reduced form in the prostate and other tissues. Thus, administration of these compounds--testosterone derivatives with a non-hydrogen substituent in the 6α or 7α position--allows one to provide androgen supplementation therapy without stimulating abnormal prostate growth. A preferred compound for use in the invention is 7α-methyl-19-nortestosterone.